CY1110577T1 - Διαγνωση της νοσου alzheimer με αναλυση πολυμορφισμων γονιδιου il-10 - Google Patents
Διαγνωση της νοσου alzheimer με αναλυση πολυμορφισμων γονιδιου il-10Info
- Publication number
- CY1110577T1 CY1110577T1 CY20091101286T CY091101286T CY1110577T1 CY 1110577 T1 CY1110577 T1 CY 1110577T1 CY 20091101286 T CY20091101286 T CY 20091101286T CY 091101286 T CY091101286 T CY 091101286T CY 1110577 T1 CY1110577 T1 CY 1110577T1
- Authority
- CY
- Cyprus
- Prior art keywords
- production
- ata
- acc
- patients
- amyloid
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 8
- 108090000174 Interleukin-10 Proteins 0.000 title abstract 5
- 238000003745 diagnosis Methods 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 230000031261 interleukin-10 production Effects 0.000 abstract 4
- 102000003814 Interleukin-10 Human genes 0.000 abstract 3
- 229940076144 interleukin-10 Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000008506 pathogenesis Effects 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004073 interleukin-2 production Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003226 mitogen Substances 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
Abstract
Προτείνεται να ενέχεται μία φλεγμονώδης διεργασία στην παθογένεση της νόσου Alzheimer (AD), μιας νευροεκφυλιστικής διαταραχής που χαρακτηρίζεται από την παρουσία νευριτικών πλακών εντός του εγκεφαλικού φλοιού που κυρίως αποτελούνται από μία μικρή αδιάλυτη πρωτεΐνη 40-42 αμινοξέων (αμυλοειδής πρωτεΐνη). Οι βιολογικές σχέσεις αυτής της διεργασίας εντούτοις δεν είναι σαφείς. Η Ιντερλευκίνη-10 (IL-10) είναι μία κυτοκίνη που καταστέλλει Τ λεμφοκύτταρα και προκαλούμενη από κύτταρο ανοσία στους ανθρώπους και τους ποντικούς και έχει ισχυρές αντι-φλεγμονώδεις ιδιότητες. Για να πιστοποιηθεί εάν η παραγωγή IL-10 μπορεί να είναι εξασθενημένη σε ασθενείς με AD διεγείραμε PBMC από 47 ασθενείς και 25 της ίδιας ηλικίας υγιή δείγματα αναφοράς (HC) με ένα μιτογόνο, ένα αντιγόνο ανάκλησης ή με αμυλοειδή πεπτίδια. Μετρήθηκε επίσης παραγωγή IL-2 στις ίδιες συνθήκες καλλιέργειας. Τα αποτελέσματα έδειξαν ότι αμυλοειδούς-ειδική δημιουργία IL-10 εκλεκτικώς και σημαντικώς μειώνεται σε ασθενείς με AD (p = 0,023). Αναλύσεις επί των αλληλίων του IL-10 γονιδίου απεκάλυψαν ότι ο γονότυπος που συνδυάζεται με υψηλή παραγωγή IL-10 είναι εξαιρετικά σπάνιος σε άτομα με AD (2% έναντι 28%). Η παρουσία χαμηλών/ενδιαμέσων γονότυπων παραγωγής IL-10 (GCC/ATA, ΑΤΑ/ΑΤΑ) συνδυάστηκε με εμφάνιση της ασθένειας σε μία προγενέστερη ηλικία και (ACC/ACC, ACC/ATA) με επιταχυνόμενο ρυθμό προόδου ασθένειας. Αυτά τα δεδομένα έριξαν φως στην βιολογία της φλεγμονώδους διεργασίας που ενέχεται στην παθογένεση της AD δείχνοντας ότι η παρουσία χαμηλών-IL-10-αλληλικών ισόμορφων έχει σαν αποτέλεσμα αμυλοειδούς-ειδική εξασθένιση της παραγωγής IL-10 και συνδυάζεται με την κλινική σοβαρότητα της AD. Αυτά τα αποτελέσματα οδήγησαν να υποστηρίζεται η χρήση αντιφλεγμονωδών ενώσεων στην θεραπεία αυτής της
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212648.0A GB0212648D0 (en) | 2002-05-31 | 2002-05-31 | Treatment with cytokines |
| EP03740698A EP1509621B1 (en) | 2002-05-31 | 2003-05-30 | Diagnostic of alzheimer's disease by analysis of il-10 gene polymorphisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110577T1 true CY1110577T1 (el) | 2015-04-29 |
Family
ID=9937825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101286T CY1110577T1 (el) | 2002-05-31 | 2009-12-09 | Διαγνωση της νοσου alzheimer με αναλυση πολυμορφισμων γονιδιου il-10 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050260767A1 (el) |
| EP (1) | EP1509621B1 (el) |
| JP (1) | JP4504186B2 (el) |
| AT (1) | ATE442455T1 (el) |
| AU (1) | AU2003273534A1 (el) |
| CA (1) | CA2487734C (el) |
| CY (1) | CY1110577T1 (el) |
| DE (1) | DE60329179D1 (el) |
| DK (1) | DK1509621T3 (el) |
| ES (1) | ES2333312T3 (el) |
| GB (1) | GB0212648D0 (el) |
| PL (1) | PL214984B1 (el) |
| PT (1) | PT1509621E (el) |
| RU (2) | RU2337142C2 (el) |
| SI (1) | SI1509621T1 (el) |
| WO (1) | WO2003102237A1 (el) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1335741A4 (en) * | 2000-08-25 | 2005-10-26 | Yeda Res & Dev | METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02) |
| WO2002026265A2 (en) | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
| US20070248955A1 (en) * | 2003-10-06 | 2007-10-25 | Novartis Ag | Use Of Genetic Polymorphisms To Predict Drug-Induced Hepatotoxicity |
| WO2005080594A2 (en) * | 2004-02-24 | 2005-09-01 | Innogenetics N.V. | Method for determining the risk of developing a neurological disease |
| GB0412859D0 (en) * | 2004-06-09 | 2004-07-14 | Immunoclin Ltd | Markers for atherosclerosis |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| WO2006119170A2 (en) * | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| AU2007314501B2 (en) | 2006-09-28 | 2013-05-23 | Merck Sharp & Dohme Corp. | Use of pegylated IL-10 to treat cancer |
| RU2471487C2 (ru) * | 2007-02-06 | 2013-01-10 | Тай Джун ЙОО | Лечение и предупреждение нейродегенеративных заболеваний с использованием генной терапии |
| RU2549702C2 (ru) | 2008-12-17 | 2015-04-27 | Мерк Шарп И Доум Корп., | Получение и применение моно- и ди-пэг il-10 |
| ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| HUE042463T2 (hu) | 2013-07-18 | 2019-07-29 | Univ Colorado Regents | Készítmény gyulladásos ízületi betegség kezelésére |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| RU2016122957A (ru) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| AU2015333827A1 (en) | 2014-10-14 | 2017-04-20 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| KR20170084033A (ko) | 2014-10-22 | 2017-07-19 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법 |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| WO2017035232A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0760098A4 (en) * | 1994-06-09 | 1997-07-16 | Univ Bar Ilan | DIAGNOSIS OF THE PATHOLOGICAL PHASE OF ALZHEIMER'S DISEASE BASED ON CYONKIN SECRETIONS BY MONONUCLEAR CELLS |
| RU2176914C2 (ru) * | 1995-05-30 | 2001-12-20 | Эли Лилли Энд Компани | Способ лечения нарушения познавательной функции |
-
2002
- 2002-05-31 GB GBGB0212648.0A patent/GB0212648D0/en not_active Ceased
-
2003
- 2003-05-30 PT PT03740698T patent/PT1509621E/pt unknown
- 2003-05-30 AU AU2003273534A patent/AU2003273534A1/en not_active Abandoned
- 2003-05-30 AT AT03740698T patent/ATE442455T1/de active
- 2003-05-30 DE DE60329179T patent/DE60329179D1/de not_active Expired - Lifetime
- 2003-05-30 WO PCT/GB2003/002369 patent/WO2003102237A1/en active Application Filing
- 2003-05-30 JP JP2004510473A patent/JP4504186B2/ja not_active Expired - Fee Related
- 2003-05-30 SI SI200331708T patent/SI1509621T1/sl unknown
- 2003-05-30 DK DK03740698.0T patent/DK1509621T3/da active
- 2003-05-30 PL PL374343A patent/PL214984B1/pl unknown
- 2003-05-30 RU RU2004139089/13A patent/RU2337142C2/ru not_active IP Right Cessation
- 2003-05-30 US US10/516,421 patent/US20050260767A1/en not_active Abandoned
- 2003-05-30 EP EP03740698A patent/EP1509621B1/en not_active Expired - Lifetime
- 2003-05-30 CA CA2487734A patent/CA2487734C/en not_active Expired - Fee Related
- 2003-05-30 ES ES03740698T patent/ES2333312T3/es not_active Expired - Lifetime
-
2008
- 2008-04-28 RU RU2008116925/10A patent/RU2519651C2/ru not_active IP Right Cessation
-
2009
- 2009-12-09 CY CY20091101286T patent/CY1110577T1/el unknown
-
2012
- 2012-01-23 US US13/356,374 patent/US20120214866A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE442455T1 (de) | 2009-09-15 |
| ES2333312T3 (es) | 2010-02-19 |
| RU2008116925A (ru) | 2009-11-10 |
| EP1509621B1 (en) | 2009-09-09 |
| PL374343A1 (en) | 2005-10-17 |
| RU2004139089A (ru) | 2005-08-10 |
| JP2005528119A (ja) | 2005-09-22 |
| GB0212648D0 (en) | 2002-07-10 |
| PT1509621E (pt) | 2009-12-17 |
| DK1509621T3 (da) | 2010-01-18 |
| US20050260767A1 (en) | 2005-11-24 |
| RU2519651C2 (ru) | 2014-06-20 |
| EP1509621A1 (en) | 2005-03-02 |
| JP4504186B2 (ja) | 2010-07-14 |
| DE60329179D1 (de) | 2009-10-22 |
| AU2003273534A1 (en) | 2003-12-19 |
| CA2487734C (en) | 2012-03-06 |
| SI1509621T1 (sl) | 2010-03-31 |
| PL214984B1 (pl) | 2013-10-31 |
| WO2003102237A1 (en) | 2003-12-11 |
| CA2487734A1 (en) | 2003-12-11 |
| RU2337142C2 (ru) | 2008-10-27 |
| US20120214866A1 (en) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110577T1 (el) | Διαγνωση της νοσου alzheimer με αναλυση πολυμορφισμων γονιδιου il-10 | |
| Su et al. | Inflammatory cytokines and Alzheimer’s disease: a review from the perspective of genetic polymorphisms | |
| Silva et al. | Analysis of HSPA8 and HSPA9 mRNA expression and promoter methylation in the brain and blood of Alzheimer's disease patients | |
| Camarena et al. | PSMB8 (LMP7) but not PSMB9 (LMP2) gene polymorphisms are associated to pigeon breeder's hypersensitivity pneumonitis | |
| Jafarzadeh et al. | Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern | |
| Wróbel et al. | IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia | |
| D’Souza et al. | Type I Interferon signaling controls the accumulation and transcriptomes of monocytes in the aged lung | |
| Durmanova et al. | A Novel Association of Polymorphism in the ITGA4 Gene Encoding the VLA‐4 α4 Subunit with Increased Risk of Alzheimer’s Disease | |
| Zhu et al. | Correlation between acute myeloid leukemia and IL-17A, IL-17F, and IL-23R gene polymorphism | |
| Ngassa Mbenda et al. | Genetics of HIV-associated sensory neuropathy and related pain in Africans | |
| Pae et al. | Tumor necrosis factor‐α gene polymorphism at position− 308 and schizophrenia in the Korean population | |
| Depboylu et al. | An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer’s disease | |
| CN111575362B (zh) | 一种预测系统性红斑狼疮疾病活动度的药物 | |
| Gontika et al. | Human leukocyte antigens‑immunogenetics of neuromyelitis optica or Devic’s disease and the impact on the immunopathogenesis, diagnosis and treatment: a critical review | |
| US20140193440A1 (en) | Markers of alzheimers disease | |
| Biernacka-Lukanty et al. | Polymorphism of the osteopontin gene and clinical course of multiple sclerosis in the Polish population | |
| Said et al. | Association between viral Conjunctivitis and Genetic Polymorphisms related to IL-4 and IL-4R in Egyptian Population | |
| Kessler et al. | OP0153 BROADENING OUR UNDERSTANDING OF THE GENETICS OF JUVENILE IDIOPATHIC ARTHRITIS: INTERROGATION OF THREE DIMENSIONAL CHROMATIN STRUCTURES WITHIN JIA-ASSOCIATED RISK LOCI | |
| Mesbah-Amroun et al. | Apolipoprotein E Genotypes in Alzheimer's Disease in Central Algerian Population | |
| DAMAYANTI et al. | INTERLEUKIN AS BIOMARKER OF RECURRENT APHTHOUS STOMATITIS (RAS): A SYSTEMATIC LITERATURE REVIEW | |
| Barbieux et al. | Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-a and allergic responses | |
| Saberi et al. | The Relationship Between Bridging Integrator 1 Gene Polymorphism and Susceptibility to Alzheimer’s Disease | |
| Durmanova et al. | Research Article A Novel Association of Polymorphism in the ITGA4 Gene Encoding the VLA-4 α4 Subunit with Increased Risk of Alzheimer’s Disease | |
| Nakashima et al. | Association between IFNA genotype and the risk of systemic lupus erythematosus | |
| Katsounas et al. | Microarrays-Enabled Hypothesis Generation: The Suspect Role of FNBP-1 in Neuropsychiatric Pathogenesis Associated with HIV and/or HCV Infection |